Kingstronics (青石永隽)

Operating within the competitive neurotechnology and neuromodulation landscape, Kingstronics differentiates itself through its academic roots at Zhejiang University and a specialized focus on treatment-resistant depression via adaptive deep brain stimulation (aDBS). Unlike traditional psychiatric interventions, the company combines neural target localization, emotional biomarker tracking, and closed-loop stimulation. While competing against established medical device manufacturers in the neuromodulation space, Kingstronics leverages its proprietary 16-channel local field potential recording capabilities and custom digital neuroelectrophysiology systems to carve out a distinct position in mental health therapeutics.

Kingstronics has demonstrated steady organizational and technical expansion since its inception, marked by the completion of angel and angel-plus financing rounds totaling RMB 90 million. The company's trajectory is defined by a transition from academic research into full-scale product development and intelligent manufacturing. By establishing dedicated cleanroom facilities for micro- and nanofabrication, Kingstronics has built the internal infrastructure necessary to scale its animal studies, clinical research, and global supply chain operations, positioning itself for broader clinical evaluations of its brain-computer interface computing and stimulation platforms.